AAIC 2025 Abstract
Evaluating the Efficacy and Risks of Early Lecanemab Treatment in APOE4 Humanized Alzheimer's Disease Mouse Models
Experiments in animalsInterventions
Abstract
Background: Alzheimer's disease (AD) is the leading cause of dementia. AD disproportionately affects APOE4 carriers, who experience accelerated amyloid β (Aβ) accumulation, including cerebral amyloid angiopathy (CAA).
